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ABSTRACT
Tumor microenvironment has been described to play a key role in tumor growth, 
progression, and metastasis. Macrophages are a major cellular constituent of the 
tumor stroma, and particularly tumor associated macrophages (TAMs or M2-like 
macrophages) exert important immunosuppressive activity and a pro-tumoral role 
within the tumor microenvironment. Alternative-reading frame (ARF) gene is widely 
inactivated in human cancer. We have previously demonstrated that ARF deficiency 
severely impairs inflammatory response establishing a new role for ARF in the 
regulation of innate immunity. On the basis of these observations, we hypothesized 
that ARF may also regulates tumor growth through recruitment and modulation of the 
macrophage phenotype in the tumor microenvironment. Xenograft assays of B16F10 
melanoma cells into ARF-deficient mice resulted in increased tumor growth compared 
to those implanted in WT control mice. Tumors from ARF-deficient mice exhibited 
significantly increased number of TAMs as well as microvascular density. Transwell 
assays showed crosstalk between tumor cells and macrophages. On the one hand, 
ARF-deficient macrophages modulate migratory ability of the tumor cells. And on the 
other, tumor cells promote the skewing of ARF–/– macrophages toward a M2-type 
polarization.  In conclusion, these results demonstrate that ARF deficiency facilitates 
the infiltration of macrophages into the tumor mass and favors their polarization 
towards a M2 phenotype, thus promoting tumor angiogenesis and tumor growth. 
This work provides novel information about the critical role of ARF in the modulation 
of tumor microenvironment.
INTRODUCTION
Tumor microenvironment plays a critical role 
in cancer initiation, progression and metastasis [1, 2]. 
One of the major cellular components in the tumor 
microenvironment are macrophages [3, 4]. Macrophages 
are a heterogeneous population of immune cells that 
have been divided in two major types according to 
surface receptors, cytokine production and reactivity: the 
classically activated M1 and the alternatively activated M2 
[3]. M1 macrophages are induced by cytokines as IFN-γ, 
TNF-α, and granulocyte–macrophage colony stimulating 
factor (GM-CSF) or microbial stimuli like LPS from gram-
negative bacteria. M1 macrophages produce large amounts 
of pro-inflammatory cytokines, superoxide anions, 
and oxygen radicals, exhibiting cytotoxicity toward 
microorganisms and anti-tumor activity [5]. Conversely, 
stimuli such as the Th2 cytokines IL-4/IL-13 induce M2 
macrophages that have been suggested to contribute to 
angiogenesis, tissue remodeling, and tumor progression 
[3, 5]. Interestingly, prolonged exposure to inflammatory 
stimuli such as LPS or tumor cells can also lead to a M2 
state, illustrating that macrophage polarization is a highly 
dynamic process where macrophages can easily switch 
from one phenotype to the other [6].
Tumor-associated macrophages (TAMs) are generally 
thought to resemble M2-type and have been widely 
associated with progression of tumors via proangiogenic 
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factors release [7, 8]. TAMs also exert immunosuppressive 
functions through the release of anti-inflammatory 
cytokines, including IL-10 and TGF-β, and modulate the 
tumor microenvironment by producing survival factors 
(e.g., VEGF) [3, 5, 7, 8]. Indeed, abundance of TAMs has 
been correlated with a poor prognosis in human cancers 
such as breast, prostate, ovarian, cervical, lung carcinoma, 
and cutaneous melanoma [8, 9]. 
Tumor suppressor ARF is among the most frequent 
genes mutated in human cancer [10]. ARF encoded by 
the INK4a/ARF locus (Cdkn2a) generates two unrelated 
proteins, the cyclin-dependent kinase inhibitor p16INK4a 
and ARF, which, respectively, regulate the activity of 
retinoblastoma and the p53 transcription factor [11, 12]. 
Although, it is widely assumed that ARF can suppress 
tumor growth through p53 regulation, numerous lines of 
evidence suggest that ARF has additional p53-independent 
tumor suppressor activities [5, 13]. Interestingly, tumors 
that arise in ARF−/− versus p53−/− mice are different 
both in types and frequencies [14]. Together with the 
tumor suppressor function, ARF has been described 
to play an important role in the regulation of innate 
immunity and inflammatory processes. ARF-deficient 
macrophages have been reported to exhibit an impaired 
ability to develop pro-inflammatory properties showing 
a relevant downregulation of genes involved in M1 
macrophage phenotype [15]. Furthermore, mice lacking 
the ARF gene are resistant to LPS-endotoxic shock [15]. 
Therefore, ARF might modulate the M1/M2 polarization 
and functional plasticity of macrophages. Indeed, we have 
previously described that ARF-deficient macrophages 
exhibit polarization towards a M2 phenotype [16]. On 
the basis of these observations, we hypothesized that 
ARF may also regulate tumor growth through inhibiting 
macrophage recruitment and M2 polarization in the 
tumor microenvironment. Our data demonstrate that 
ARF deficiency not only enhances the growth of B16F10 
tumors but also increases macrophage infiltration 
and angiogenesis in the xenograft model. Analysis of 
macrophage population indicates that most of these 
cells show a M2-like phenotype. In addition, tumor cell 
interaction with ARF−/− macrophages results in induction 
of tumor cell migration and skew ARF−/− macrophages 
to a more prone M2 phenotype. These data provide novel 
insights about the role of ARF on the regulation of tumor 
growth via modulation of tumor microenvironment. 
RESULTS
ARF deficiency promotes tumor growth and 
TAM infiltration in a B16F10 melanoma 
xenograft model
Based on our previous studies reporting that ARF 
deficiency severely impairs inflammatory response and 
induces macrophages polarization towards a M2-phenotype 
[15, 16], we wondered whether ARF would also modulate 
tumor microenvironment in vivo. Thus, B16F10 cells were 
injected subcutaneously into the flank of WT or ARF−/− 
mice, and after 15 days the generated tumors were analyzed. 
As expected, ARF deficiency resulted in an increase 
of tumor growth compared to WT animals (Figure 1A 
and 1B). Hematoxylin/Eosin (H/E) histological analyses of 
the tumor sections showed that whereas the fibrous capsule 
surrounding tumors was thin in WT mice, B16F10-ARF−/− 
tumors displayed a wide fibrous capsule with a well-
defined border along the tumor parenchyma (Figure 1C). 
Interestingly, this fibrous capsule showed an excess of 
fibrous connective tissue and collagen deposition compared 
to WT animals as revealed by Sirius red/Fast green staining 
(Figure 1D).  
Next, we evaluated the macrophages content by 
immunohistochemical staining using the pan-macrophage 
marker F4/80. Although macrophage infiltration was 
observed in both cases, the number of F4/80-positive 
macrophages was significantly higher in the center and 
the periphery of the tumors generated on ARF−/− mice 
compared to the ones on WT (Figure 2A). 
TAMs are reported to express a marker profile 
similar to M2 macrophages including expression of the 
mannose receptor CD206 [8]. Co-staining for CD206 and 
F4/80 revealed that CD206 expression was exclusively 
detectable in macrophages but not in tumor cells and 
that B16F10-ARF−/− tumor xenografts had greater 
numbers of double-positive cells than B16F10-WT tumor 
xenografts (Figure 2B). These data strongly suggest that 
ARF deficiency promotes the recruitment of macrophages 
into the tumors and their polarization towards the M2 
phenotype.
Tumor angiogenesis is enhanced in tumors 
developed in ARF–/– mice 
Angiogenesis plays an important role in the 
progression of tumor. Besides being regulated by tumor 
cells, TAMs have been also described to promote 
angiogenesis [3, 17]. In addition, ARF has been reported 
to modulate tumor vascularity via VEGF expression 
[18–20] and it is required for vascular remodeling in late 
stages of mouse eye development [21]. This prompted 
us to determine whether the increased tumor growth 
and macrophage infiltration observed in the ARF−/− 
mice correlated with a higher vascularity degree. 
Immunohistochemical and immunofluorescence analysis 
of vascular density using CD31 staining showed that 
tumor angiogenesis was significantly increased in ARF−/− 
mice compared to WT animals (Figure 3A and 3B). 
Furthermore, presence of lumen on the majority of new 
vessels of ARF−/− tumors indicate a more mature and 
organized vasculature (Figure 3A, asterisk).  In addition, 
higher presence of α-smooth muscle actin (α-SMA)-
positive cells was detected in B16F10-ARF−/− tumor 
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xenografts (Figure 3C). Double staining using CD31 and 
α-SMA antibodies revealed a developed and organized 
α-SMA-positive tissue surrounding the endothelial 
compartment in the B16F10-ARF−/− tumor xenografts, 
confirming a more mature and functional vasculature in 
ARF−/− tumor xenografts (Figure 4A). Interestingly, 
staining with F4/80 showed dense areas of macrophages 
adjacent to the vessels in tumors generated on ARF−/− 
mice (Figure 4A). Positive expression of CD206 in 
consecutive sections demonstrates that most of these cells 
were M2 macrophages, suggesting that these cells were 
interacting with the vascular bed (Figure 4B).  
Figure 1: Increased tumor growth and fibrous capsule in B16F10-ARF−/− tumor xenografts. ARF−/− or WT mice 
(n = 6) were inoculated subcutaneously with B16F10 cells (3 × 105) and tumor phenotype was analyzed at 15 days post injection. 
(A) Representative images of WT and ARF−/− tumor xenografts at day 15. (B) Tumor weight (g) and tumor volume (cm3) on day 15 after 
B16F10 cell inoculation. Data are means ± S.D. P < 0.01 (C) Representative histology of tumors from WT and ARF−/− mice stained with 
H/E. (D) Representative histology of tumors from WT and ARF−/− mice stained with Sirius Red/Fast green. 
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ARF deficiency modifies molecular pathways 
that regulate the tumor immune responses and 
angiogenesis
In addition to the histological studies, we analyzed 
the expression of several M2 markers in the tumor 
tissues collected from the melanoma xenograft model. 
Expression of Arginase-1 (Arg-1), Found in inflammatory 
zone-1 (Fizz-1), chitinase 3-like-3 (Ym- 1), mannose 
receptor (MRC1/CD206) and Macrophage galactose-
type C-type lectins 2 (MGL-2) were increased in 
B16F10-ARF−/− tumor xenografts, confirming M2 
polarization of macrophages (Figure 5A). We also 
evaluated a panel of cytokines and chemokines related 
to recruitment and M2 polarization of macrophages. 
Quantitative PCR analysis reported that ARF deficiency 
significantly upregulated mRNA levels of IL-10, TGF-β, 
CCL-17, CCL-22 and CCL-5 in tumors (Figure 5B). 
In an attempt to identify the mechanism involved in 
the angiogenic response on B16F10-ARF−/− tumor 
xenografts, first we analyzed expression of an array of 
angiogenesis-related genes by quantitative PCR. The 
mRNA levels of VEGF receptor-2 (VEGFR-2), vascular 
endothelial cadherin (VE-cadherin), and adhesion 
molecules as VCAM-1, PECAM-1/CD31 and ICAM- 1 
notably increased in ARF−/− tumors compared to 
WT (Figure 5C). Nevertheless, other factors known to 
modulate angiogenesis and endothelial cell migration, 
such as VEGF or endoglin, remained unchanged 
(Supplementary Figure S1A). Since it has been described 
Figure 2: ARF deficiency enhances recruitment and activation of macrophages to acquire M2 phenotype. ARF−/− or 
WT mice were inoculated subcutaneously with B16F10 cells (3 × 105) and tumor phenotype was analyzed at 15 days post injection. 
(A) Left panel shows representative immunohistochemistry of tumors from WT or ARF−/− mice stained with anti-F4/80. Right panel 
shows quantification of F4/80+ macrophages in B16F10 tumors isolated from ARF−/− or WT animals. Macrophages were counted blindly 
in 5–10 randomly chosen fields and data are means ± S.D. of three independent experiments with 4 mice each. (B) Left panel shows 
immunolocalization of F4/80 (pan macrophage marker, red) and CD206/ (M2 macrophage marker, green) in the tumor sections from WT 
and ARF−/− mice. The slices were counterstained with DAPI (blue) and analyzed by confocal microscopy. Right panel shows increase 
of M2 macrophages in B16F10 tumors from ARF−/− mice as compared to WT animals. Number of double positive F4/80 and CD206 
macrophages was counted blindly in 5–10 randomly chosen fields and data are means ± S.D. of three independent experiments with 4 mice 
each. **P < 0.01 and ***P < 0.001. 
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that ARF inhibits angiogenesis by stimulating the 
expression of tissue inhibitor of metalloproteinase-3 
(TIMP-3) [22], and TIMP-3 has been shown to inhibit 
VEGFR-2 and adhesion molecules as VE-cadherin or 
VCAM- 1 [23– 25], we further explored levels of TIMP- 3 
in B16F10-ARF−/− tumor xenografts. Our data show 
that mRNA expression and protein levels of TIMP-3 
were decreased in ARF−/− tumor xenografts compared 
to WT tumor xenografts (Figure 5D and 5E). Notably, the 
mRNA levels of the TIMP-3 substrates belonging to the 
matrix metalloproteinase family, MMP-2 and MMP-9, 
remained unchanged (Supplementary Figure S1B).  
Figure 3: Tumor angiogenesis is increased in ARF−/− tumor xenografts. ARF−/− or WT mice were inoculated subcutaneously 
with B16F10 cells (3 × 105) and tumor phenotype was analyzed at 15 days post injection. (A) Left panel shows representative 
immunohistochemistry of tumors grown on WT or ARF−/− mice stained with anti-CD31. A single microvessel was defined as a discrete 
cluster of CD31 positive cells, with no requirement for the presence of lumen. Quantification of microvessel density (MVD) was performed 
on microscope images from 5–10 randomly chosen fields of each tumor sample and data are represented as means ± S.D. Presence of 
lumen (asterisks) indicates a more mature vasculature. (B) Evaluation of tumor vasculature by confocal microscopy using CD31 antibody. 
Vessel density was quantified as mean fluorescence intensity (MFI) from the endothelial CD31 positive staining on 5–10 randomly chosen 
fields of each sample using the Image J software. Data are represented as means ± S.D. (C) Evaluation of α-SMA positive cells by confocal 
microscopy on samples from xenografts generated on WT and ARF−/− mice. Mean fluorescence intensity of α-SMA positive signal was 
quantified by Image J as in B).  *P < 0.05, and ***P < 0.001.
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Analysis of gene expression have been performed 
in whole tumors, consisting in a mixed of tumor and 
stromal cells, including immune and vascular cells. To 
further explore the role of ARF−/− macrophages on the 
modulation of angiogenesis, we isolated TAMs from 
B16F10 tumor xenografts and examined gene expression 
of some of the genes involved in M2 polarization (e.g. 
Ym-1 and MRC1) as well as in the angiogenic response. 
In line with the data obtained in whole tumors, TAMs 
isolated from B16F10-ARF−/− tumor xenografts exhibited 
higher expression of typical M2 markers Ym-1 and 
MRC1 when compared to TAMs from B16F10-WT tumor 
xenografts (Figure 6A). In addition, mRNA expression of 
TIMP-3 was also decreased in ARF−/− TAMs (Figure 6B) 
confirming our previous results. Interestingly, we observed 
an increased expression of the TIMP-3 substrates, MMP-2 
and MMP-9, as well as VEGF (Figure 6C). 
Finally, given the differences in the genetic 
programs activated in mouse and human in the context 
of M2 polarization, next we evaluate the universality of 
ARF in the alternative activation of macrophages. To 
do that, we silenced p14ARF in the human monocytic 
Figure 4: Tumor blood vessels developed in ARF−/− xenografts were associated with higher number of M2 macrophages. 
ARF−/− or WT mice were inoculated subcutaneously with B16F10 cells (3 × 105) and tumor phenotype was analyzed at 15 days post 
injection. (A) Immunofluorescence staining of CD31 (red), α-SMA (green) and F4/80 (white) in tumor sections from WT and ARF−/− mice 
(left). Samples were counterstained with DAPI (blue) and analyzed by confocal microscopy. Number of macrophages associated with 
mature angiogenic vessels (endothelial layer surrounded by α-SMA cells) was evaluated on five random fields of 10 independent tumor 
sections (Right). (B) Immunofluorescence staining of CD206 (green) in consecutive tumor sections from WT and ARF−/− mice (left). 
Samples were counterstained with DAPI (blue) and analyzed by confocal microscopy. White arrows indicate M2 macrophages. Right 
graphic shows number of CD206 positive cells associated with mature angiogenic vessels from five random fields of 10 independent tumor 
sections. Data are means ± S.D. **P < 0.01 and ***P < 0.001.
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Figure 5: Effects of ARF deficiency on immune and angiogenic pathways. mRNA expression of (A) M2 markers (Arg- 1, 
Fizz-1, Ym-1, MRC1/CD206, MGL-2), (B) cytokines and chemokines (IL-10, TGF-β, CCL-17, CCL-22, CCL-5), (C) angiogenic 
factors (VEGFR2, VE-cadherin, VCAM-1, PECAM-1/CD31, ICAM-1) and (D) inhibitors of angiogenesis (TIMP-3) were evaluated by 
quantitative PCR in tumor xenografts from WT and ARF−/− mice. In all cases, mRNA induction levels were normalized to 36B4 mRNA 
expression. Data are means of each group ± S.D. (n = 6). *P < 0.05, **P < 0.01 and ***P < 0.001.  (E) Western blot analysis of the protein 
levels of TIMP-3 in tumors from WT or ARF−/− mice. Numbers (1, 2, 3) indicate different animals of the same group. Band intensity of 
Western blots was analyzed by densitometry, normalized to β-actin levels and represented as the mean ± SD of the fold change from control 
condition (n = 3). *p < 0.05 with respect to WT mice.
Oncotarget66842www.impactjournals.com/oncotarget
cell line THP-1 by small interfering RNA (siRNA), and 
analyzed human M2 markers. Silencing of p14ARF in 
THP-1 cells resulted in a significant increment in IL-10 and 
YKL- 40 expression. These results confirm the general role 
of ARF in the regulation of macrophage polarization, at least 
for human and mice species (Supplementary Figure S2).
Taken together, our data suggest that loss of ARF 
might lead to the activation of genetic programs that 
regulate the immune response, specially promoting M2 
polarization of macrophages, and tumor angiogenesis.
ARF−/− macrophages enhance migration 
abilities of tumor and endothelial cells in vitro
Based on the earlier results from the xenograft 
studies, we propose that ARF deficiency plays a 
critical role in tumor growth by modulating the tumor 
microenvironment via M2-macrophage polarization 
and thereby tumor cells properties. To test whether ARF 
modulates migration of tumor cells via macrophage 
polarization, we co-cultured B16F10 cells with 
macrophages from WT and ARF−/− mice separated by 
a porous membrane on a Boyden chamber assays, and 
tumor cells migration was evaluated after 24 h incubation 
as described in the Materials and Methods section. We 
found that the number of migrated cancer cells increased 
significantly in the presence of ARF−/− macrophages 
compared to WT macrophages (Figure 7A). In addition 
similar results were observed in a scratch-wound migration 
assay when tumor cells were co-cultured with ARF−/− 
macrophages (Figure 7B). Since cell to cell contact does 
not take place in this set of experiments, these results 
suggest that the soluble factors released from macrophages 
are the responsible for the migratory activity of tumor 
cells. To further confirm this idea, we performed scratch-
wound migration assay of B16F10 cells in the presence 
of macrophages conditioned media. In agreement with 
previous result, conditioned medium (CM) from ARF−/− 
macrophages induced higher migration rate of B16F10 
cells compared to when supernatant from WT macrophages 
was added (Supplementary Figure S3). Interestingly, 
B16F10 cell proliferation was not affected by incubation 
with ARF−/− or WT macrophages cultured under separated 
semipermeable membrane (Supplementary Figure S4). 
Since we have reported a higher vascularity degree 
in the B16F10-ARF−/− tumor xenografts (Figure 3) 
with dense areas of macrophages adjacent to the vessels 
(Figure 4), we also evaluated whether ARF−/− macrophages 
may regulate endothelial migration. Using the scratch-
wound assay, we have observed that conditioned medium 
obtained from ARF−/− macrophages induce a higher 
mobility of endothelial cells (Supplementary Figure S5). 
Overall, these data demonstrated that ARF−/− 
macrophages stimulate migration of cancer and endothelial 
cells without significantly modulation of the tumor cell 
proliferation.  
Figure 6: TAMs from ARF−/− xenografts overexpressed M2 markers and modulate angiogenic genes. mRNA expression 
of (A) M2 markers (Ym-1, MRC1/CD206), (B) (TIMP-3) and (C) angiogenic factors (MMP-2, MMP-9 and VEGF) were evaluated 
by quantitative PCR in TAMs isolated from tumor xenografts from WT and ARF−/− mice. In all cases, mRNA induction levels were 
normalized to 36B4 mRNA expression. Data are means of each group ± S.D. (n = 4). *P < 0.05, and **P < 0.01 with respect to WT mice.
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Figure 7: ARF−/− macrophages promoted migration of B16F10 cells. Peritoneal macrophages from WT and ARF−/− mice were 
isolated as previously described. (A) Migration analysis was carried out using Boyden chamber assays. B16F10 cells were platted on the 
transwell inserts whereas WT or ARF−/− macrophages were cultured on the 24-well tissue culture plate. After 24 h, inserts were stained 
with 0.5% crystal violet, and non-migrated cells were discarded from the top of the insert. Randomly chosen fields were photographed 
(×10), and the number of tumor cells migrated to the lower surface was calculated as the absorbance value at 540 nm.  Representative 
images (left) and bar graph (right) depicting the migration ability of B16F10 in the presence of ARF−/− macrophages. (B) Wound healing 
assays were performed in B16F10 cells in the presence of macrophages from WT or ARF−/− mice placed in the insert. Migration into the 
scratched area was photographed (×10) and calculated as percentage of wound closure using the Image J software. Scale bar = 200 μm. Data 
are shown as the mean ± SD of three independent experiments, *P < 0.05, **P < 0.01 and ***P < 0.001. 
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Tumor cells educate ARF−/− macrophages 
to express M2 markers related to 
immunosuppressive factors
To further explore tumor cell interaction with 
ARF−/− macrophages, we exposed WT and ARF−/− 
macrophages to conditioned medium (CM) from B16F10 
tumor cells in the absence of other exogenous stimuli. We 
observed that CM-B16F10 induced significant changes 
in the expression of the M2 markers Arg-1 and Ym-1 
(Figure 8A) in WT and ARF−/− macrophages as well as 
in activity and protein levels of Arg-1 (Figure 8B and 8C). 
Furthermore, expression levels of VEGF, MMP- 2 and 
MMP-9 were also induced in the macrophages by the 
presence of CM-B16F10 (Supplementary Figure S6). 
Additionally, expression of TIMP-3 was also decreased 
confirming our previous results (Supplementary 
Figure S6). In all cases ARF−/− macrophages displayed a 
significantly more accentuated phenotype.
Interestingly, M2-like activation and differences on 
the expression of angiogenic genes were more pronounced 
in ARF−/− macrophages when compared to WT cells, 
suggesting that tumor environment activate ARF−/− 
macrophages to reach a more prone M2 state. Indeed, 
CM-B16F10 induced morphological modifications of 
macrophages with a more elongated phenotype in ARF−/− 
macrophages (Figure 8D).  This macrophage morphology 
has been previously described to be associated with a M2 
phenotype [26, 27]. 
DISCUSSION
Tumor microenvironment is constituted by a 
heterogeneous population of nonmalignant stromal 
cells that have critical roles in tumor progression and 
metastasis [1, 2]. Among them, TAMs are the main 
cellular component in the stroma of many tumors [3, 4]. 
TAMs usually share many common features with M2 
macrophages as promoting the growth of tumors and 
inducing immune suppression [3, 5, 7, 8]. It has been 
recently described that tumor suppressor ARF plays 
an important role in the regulation of the immune 
system [15] as well as in the modulation of the M1/M2 
macrophage phenotype [5, 16]. By using an in vivo model 
of B16F10 cancer xenograft, we provide evidences that 
ARF deficiency influences tumor microenvironment, 
promoting the recruitment of macrophages into tumors 
and polarizing them towards a M2 phenotype. Histologic 
studies showed increased numbers of macrophages into 
tumors generated on ARF−/− mice. These macrophages 
exhibited a M2 phenotype as revealed positive staining 
for CD206 (MRC1) and enhanced gene expression of the 
well-established M2 markers Arg-1, Fizz-1, Ym-1, MRC1/
CD206 and MGL-2. In agreement with this result, TAMs 
isolated from tumors of ARF−/− mice as well as ARF−/− 
macrophages exposed to the CM from B16F10 tumor 
cells exhibited higher expression of typical M2 polarized 
markers. Broadening this study to humans showed that 
silencing ARF in human monocyte-macrophage cells also 
resulted in a significant increase of M2 markers. Together 
all, these data confirm that ARF seems to play an important 
role in the regulation of macrophage polarization, at least 
for human and mice species.
Regarding the mechanisms involved in the 
increased recruitment of macrophages into ARF−/− tumor 
xenografts, upregulation of chemokines and growth 
factors including CCL-17, CCL-22, CCL-5 and TGF-β 
might be critical. For instance, high levels of CCL-5, 
produced by tumor cells, fibroblasts, endothelial cells, and 
even TAMs themselves, have been shown to positively 
correlate with TAM numbers in tumors [28]. Furthermore, 
these chemokines not only act as chemoattractants but 
also stimulate monocytes to express proteins that amplify 
monocyte recruitment and contribute to the tumor 
progression for example via MMP-9 secretion [28]. 
Besides, the expression of appropriate adhesion molecules 
is required for the effective leukocyte interaction with the 
endothelial surface and later extravasation to the targeted 
tissue [29].  Our results have shown that the expression 
of endothelial adhesion molecules as VCAM-1 and 
ICAM- 1 was notably increased in B16F10-ARF−/− tumor 
xenografts which may also contribute to macrophages 
recruitment [30]. In addition, preliminary results from 
our group showed a significant increase in the expression 
of β1 integrins on resting bone marrow ARF deficient 
cells (data not shown) and of α4/β1 integrin in ARF−/− 
macrophages (Table 1) suggesting that ARF-deficient 
monocytes/macrophages might also exhibit certain 
predisposition for extravasation. These findings suggest 
that tumor environment in the ARF−/− scenery favors 
the expression of adequate chemoattractants, protumoral 
mediators and adhesive partners that may facilitate the 
leukocytes recruitment and transendothelial migration.
Therefore, ARF deficiency seems to modulate the 
recruitment and polarization of macrophages into tumors. 
Consistent with our observations, ARF has been described 
to influence the expression of many genes associated with 
the innate immune response in a mouse model of acute 
leukemia upon Myc inactivation [31]. 
It is well established that TAMs have also a profound 
influence on the regulation of tumor angiogenesis 
[3, 17, 32]. Here we have observed a consistent increment 
in the number of CD31-positive cells in tumors generated 
on ARF−/− mice, suggesting new blood vessel formation. 
A more detail analysis using α-SMA staining showed a 
developed smooth muscle surrounding the endothelial 
layer within the growing tumors from ARF−/− mice, 
indicating a more mature vasculature. Consistent with 
the pro-angiogenic role of the M2 macrophages, a higher 
number of those M2 polarized cells were localized in the 
proximity of the tumor blood vessels in ARF−/− tumor 
xenografts, suggesting that these cells were interacting 
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with the vascular bed. Indeed, endothelial cells exposed to 
conditioned medium obtained from ARF−/− macrophages 
exhibited a higher mobility, supporting the role of ARF−/− 
macrophages in angiogenesis.  
TAMs have been described to induce the formation 
of new blood vessels through the expression of potent 
pro-angiogenic molecules, including VEGF or TGF-β. In 
addition, ARF has been reported to regulate endothelial 
cell proliferation and angiogenesis and to modulate tumor 
vascularity via VEGF expression; being also required 
for vascular remodeling in late stages of mouse eye 
development [20, 21, 33]. Although, we have not observed 
significant changes in VEGF levels when gene expression 
was analyzed in whole tumor, probably due to the 
existence of a mixed of tumor and stromal cells; analysis 
of TAMs isolated from the tumors of ARF−/− mice 
revealed an important increment in VEGF expression, 
similarly as was observed when ARF−/− macrophages 
were exposed to the CM from B16F10 tumor cells. In 
addition, loss of ARF resulted in a significant increase 
of the VEGFR-2 receptor, which is critical for the pro-
angiogenic effects of VEGF [34]. VEGFR-2 signaling is 
inhibited by TIMP3 via trapping VEGF and blockage of 
VE-cadherin expression on endothelial cells [23, 24]. In 
this context, inhibition of angiogenesis by ARF through 
up-regulation of TIMP3 has been reported in human 
glioma cells [22]. According to this, our work showed that 
TIMP3 expression was down regulated not only in the 
Figure 8: B16F10 cells educate ARF−/− macrophage towards a M2 phenotype. Peritoneal macrophages from WT and 
ARF−/− mice were exposed to CM from B16F10 cells (CM-B16F10). (A) Arg-1 and Ym-1 expression on macrophages was determined 
by quantitative PCR after 6 h of incubation. (B) Arginase-1 activity was measured on peritoneal macrophages after 24 h of incubation. 
(C) Protein levels of Arg-1 were determined by Western blot on WT or ARF−/− macrophages treated as in B.  Western blots are a 
representative experiment out of three. (D) Morphological changes of peritoneal macrophages from WT and ARF−/− mice exposed to 
CM- B16F10. Data are shown as the mean ± SD of three independent experiments in A and B, **P < 0.01 
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ARF−/− tumor xenograft, but also in TAMs isolated from 
the tumors of ARF−/− mice or in ARF−/− macrophages 
exposed to the CM from B16F10 tumor cells. Moreover, 
consistently with the MMP-inhibitory activity of TIMP- 3, 
its downregulation resulted in a significant increase of 
MMP-2 and MMP-9. 
Finally, expressions of VE-cadherin as well 
as TGF-β were significantly increased, presumably 
contributing to vessel development since both factors 
have been described to regulate vascular morphogenesis 
[35, 36]. These observations suggest that M2 
macrophages accumulate around blood vessels in ARF−/− 
tumor xenografts, where they would contribute to 
promote tumor vascularization, probably via modulation 
of different molecules as the axis TIMP-3/VEGFR2 or 
upregulation of VE-cadherin and TGF-β. This activation 
of the angiogenic switch might be critical for the 
accelerated tumor formation as we have not observed 
alterations in tumor cell proliferation as previously has 
been described [19].
In this work, we have shown enhanced expression 
of Ym-1 in ARF−/− tumor xenografts. Ym1 (Chi3l3) is a 
chitinase-like protein primarily expressed in mice, whereas 
humans mainly produce YKL-40. Ym-1 and YKL-40 are 
secreted from various cell types, including macrophages 
and tumor cells [37–39]. Together with the well-established 
role of Ym-1 as marker of M2 macrophage phenotype, the 
human YKL-40 has recently described to promote tumor 
angiogenesis not only as independent angiogenic factor, 
but also cooperating with VEGF [38– 40]. Therefore, 
it is tempting to speculate that this chitinase might also 
contribute to the promotion of angiogenesis in ARF−/− 
mice, although further studies on the potential role of 
YM-1/YKL-40 on angiogenesis must be required. 
In summary, we provide new evidences for the role of 
the tumor suppressor ARF on tumor growth and angiogenesis 
through modulation of the macrophages phenotype and 
rearrangement of the tumor microenvironment. These results 
might have implications for designing novel therapies based 




Studies were performed on 12-week old WT, wild 
type; and ARF−/− (knockout) mice on the C57BL/6J 
genetic background. Procedures were performed in 
accordance with the ethical standards and according to 
the Declaration of Helsinki and according to national 
and international guidelines and has been approved by 
the Ethics Committee for Animal Experimentation of the 
Instituto de Salud Carlos III (ISCIII).
Cell line cultures and tumor-conditioned media 
preparation
The murine melanoma B16F10 cell line was 
obtained from ATCC. Cells were grown at 37°C 
in DMEM medium supplemented with 10% FBS, 
penicillin (100 U/ml), and streptomycin (100 μg/ml) in a 
humidified atmosphere of 5% CO2. To collect the tumor 
or macrophages conditioned media, once grown to 90% of 
confluence, media were discarded, and flasks were rinsed 
twice with saline solution. Cells were then incubated with 
fresh DMEM for 24 h; the conditioned media (CM) was 
collected and filtered at 0.20 μm, and the supernatant was 
Table 1: Integrin expression in WT and ARF−/− macrophages 


































Peritoneal macrophages from WT and ARF−/− mice were isolated as previously described. The expression of selected 
subunits of the Integrins (ITG) family was analyzed by quantitative PCR. In all cases, mRNA levels were normalized to 36B4 
mRNA expression. Data are means ± S.D. (n = 3). Asterisks indicate significantly changed level in ARF−/− macrophages 
compared to WT cells. *P < 0.05.
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aliquoted and stored at −80°C. All cell lines were routinely 
checked for Mycoplasma contamination.
Melanoma tumor mouse model
B16F10 (3 × 105) were subcutaneously injected in 
the left flank of WT (B16F10-WT tumor xenografts) and 
ARF−/− (B16F10-ARF−/− tumor xenografts) mice. The 
mice were monitored for tumor growth every 2–3 days by 
palpation and were evaluated for changes in body weight 
and signs of discomfort or morbidity. Tumor-bearing 
animals were sacrificed at day 15 after tumor injection. 
The tumors were isolated and weighed. The final tumor 
volume was measured as 0.5 × length × width × depth 
using a Vernier caliper. 
Immunohistochemistry and immunofluorescence 
of tumors
Tumor tissues were harvested, embedded in OCT 
and sectioned with a cryostat.  Immunostaining analysis 
was performed on 5-μm cryostat sections of mouse tumor 
tissue.  Sections were stained with hematoxylin and eosin 
for histopathological examination or Sirius red/Fast green 
for evaluation of fibrous tissue and collagen content. A 
rat anti-mouse F4/80 antibody (eBioscience) was used 
for immunohistochemistry. For immunofluorescence 
staining, F4/80-APC (Miltenyi), CD206-Alexa fluor 
488 (eBioscience), CD31-PE and α-SMA-FITC (Sigma) 
were used. Then, sections were counterstained with 
4′,6-diamidino-2-phenylindole (DAPI), mounted, and 
observed under the microscope. Sections were observed 
by conventional microscopy (brightfield) (DM5500 B; 
Leica, Wetzlar, Germany) or confocal microscopy (TCS/
SP5; Leica). In all analyses, an isotype-matched control Ig 
was used as a negative control and it was confirmed that 
the positive signals were not derived from a nonspecific 
background. All images shown are representative of 
four or more independent experiments. Quantification of 
tumor vessels, characterized as CD31 positive cells, was 
performed on microscope images from 5–10 randomly 
chosen fields of each tumor sample. Vessel density 
was quantified as mean fluorescence intensity from 
the correspondent antibody-specific staining on 5–10 
randomly chosen fields of each sample tumor using the 
Image J software.
Preparation of elicited peritoneal macrophages
Peritoneal macrophages were elicited by 
intraperitoneal injection of 2.5 ml 3% thioglycollate 
in distilled water and were prepared as previously 
described [41]. Cells were seeded at 1 × 106/cm2 in 
RPMI 1640 containing 10% FBS. Nonadherent cells 
were removed 2 h after seeding by extensive washing 
with medium. 
Isolation of tumor-associated macrophages 
(TAMs)
TAMs were isolated from solid tumors according 
to literature reports [42, 43]. Briefly, tumor tissue was 
cut into 2 mm fragments, followed by collagenase 
digestion (Collagenase D 1 mg/ml) for 30 min at 37°C. 
The suspension was filtered through a 70 μm stainless 
steel wire mesh to generate a single-cell suspension. The 
suspension was centrifuged, washed twice with PBS and 
incubated with FcR bloking (BD Bioscience) for 30 min at 
4ºC. Positive selection for invasive TAMs was performed 
using rat anti-mouse CD11b antibody (BD Bioscience), 
followed by a secondary antibody-coupled magnetic 
beads (sheep anti-rat, Dynabeads®) to separate TAMs 
from the invasive carcinoma cells by a magnetic particle 
concentrator (DynaMag TM-15 Invitrogen).
Arginase activity measurement
Arginase activity was assessed in cell lysates 
indirectly by measuring urea concentration generated by 
the arginase-dependent hydrolysis of L-arginine [16]. 
Briefly, cells were lysed with 20 mM Tris (pH 7.5), 
150 mM NaCl, 2 mM EDTA, and 0.1% Triton X-100–
containing protease inhibitor mixture (Sigma) for 
30 minutes at room temperature. Standards were prepared 
by serially diluting a stock of urea (Sigma) in 50 mM 
Tris-HCl (pH 7.5) to yield a standard range from 25 to 
1500 μg/ ml.  Lysates and standards (25 μl) were mixed 
with 25 μl of 10 mM MnCl2 in 50 mM Tris-HCl (pH 7.5) 
in a 2 ml Eppendorf tube. Tubes were then incubated 
for 10 minutes at 55°C for activation. Next, arginine 
hydrolysis was conducted by incubating 50 μl of the 
lysates and standards with 50 μl of 0.5 M L-arginine at 
37°C for 75 minutes, followed by the addition of 400 μl 
stopping solution (H2SO4/H3PO4/H2O = 1/3/7, v/v/v). To 
measure the amount of urea in each tube, 50 μl of 9% 
1-phenyl-1,2-propanedione-2-oxime (Sigma) in 100% 
ethanol was added to each sample and standard, and tubes 
were incubated at 100°C for 60 minutes. Tubes were 
placed in the dark at 25°C for 30 minutes. Samples and 
standards (100 μl/well) were transferred in triplicate to 
a 96-well plate, and optical density was read at 540 nm 
with a 690 nm correction. Sample concentrations were 
determined from the standard curve and converted to 
Arginase Units using the following formula: (Urea 
Produced (μg/ml)/Total Protein (μg/ml)).
Total extracts and Western blot
Cells cultured were lysed at 4ºC with 0.2 ml buffer A 
per well (0.5% Chaps, 10 mM Tris pH 7.5, 1 mM Cl2Mg, 
1 mM EGTA, 10% Glycerol, 5 mM β-mercaptoethanol) 
and protease inhibitor cocktail (Sigma). Protein content 
was assayed with the Bio-Rad protein reagent. All cell 
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fractionation steps were carried out at 4°C. Protein 
extracts were subjected to SDS-PAGE (10–15% gels) 
and blotted onto polyvinylidene difluoride membranes 
(GE Healthcare), which were incubated with anti-Arg-1 
(sc-20150), anti-TIMP-3 (Invitrogen) and anti-β-actin 
(Sigma). After incubation with HRP-conjugated secondary 
antibody, protein bands were revealed with an enhanced 
chemiluminescence kit (GE Healthcare). β-actin was used 
as a loading control.
RNA isolation and quantitative PCR 
Total RNA was isolated from macrophages or 
melanoma tumors with Trizol reagent (Invitrogen). 
Quantitative PCR (SYBR Green) analysis was performed 
with an ABI 7500 Fast sequence analyser as described [16]. 
Each sample was run in duplicate, and all samples were 
analyzed in parallel for the expression of the housekeeping 
gene 36B4 (acidic ribosomal phosphoprotein P0), which 
was used as an endogenous control for normalization of 
the expression level of target genes. Relative expression 
was determined from mean replicate values. Primer used 
for quantitative PCR sequences are available on request. 
Migration assay
Cell migration of tumor cells was evaluated using 
transwell systems (Boyden chamber) with 8 μm pore 
size from BD Biosciences (San Diego, CA, USA) and 
according to the manufacturers’ instructions. Briefly, 
2 × 105 B16F10 cells were seeded into the upper 
chamber in serum free medium separated by a permeable 
membrane. The bottom chamber contained WT or ARF−/− 
macrophages. Serum-free medium in the bottom chamber 
was used as control. After 24 hours, cells were fixed with 
4% formaldehyde in PBS and then stained using 0.5% 
crystal violet; the cells on the upper side of the insert 
filter were completely removed by wiping with a cotton 
swab. The crystal violet was dissolved with 0.1 M sodium 
citrate, 50% ethanol, pH4,2 and the staining intensity was 
recorded as the absorbance measured at 540 nm. The A540 
value represents the number of cells that had migrated 
through the transwell. 
Scratch wound assay
Experiments were performed using transwell inserts 
with a pore size of 0.4 μm from BD Biosciences (San 
Diego, CA USA). Co-culture experiments consisted of 
adding an insert containing WT or ARF−/− macrophages 
to cultured B16F10 cells that are grown in the bottom 
compartment of the plate. B16F10 cells were grown to 
confluence on a 24-well dish in serum-free medium. A 
single stripe was scraped on the cell-coated surface with 
a disposable plastic pipette tip. After the scratch, B16F10 
cells were washed twice with PBS before the addition of 
the WT or ARF−/− macrophages inserts. Two fields per 
well were photographed at selected time points. Migration 
was analyzed using light microscopy. The area of wound 
was quantified by Image J software. The migration of 
cells toward the wounds was expressed as percentage of 
wound closure: % of wound closure= [(At = 0 h – At = Δ h)/
At = o h]x100% where, At = 0 h is the area of wound measured 
immediately after scratching, and At = Δhis the area of 
wound measured 6 or 24 h after scratching
Statistical analysis
The data presented are shown as means + SD 
of three or more independent experiments. Statistical 
significance was estimated by Student’s t. Differences 
were considered significant at *p < 0.05. All statistical 
analyses were conducted using GraphPad Prism 5.0 
(GraphPad Software). For Western blots, a linear 
correlation was observed between increasing amounts of 
input protein and signal intensity.
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